# Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

> **NCT07174141** · — · RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 100 (estimated)

## Conditions studied

- Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)

## Interventions

- **OTHER:** Ophthalmological examination
- **BIOLOGICAL:** Blood sample

## Key facts

- **NCT ID:** NCT07174141
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174141, "Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07174141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*